Skip to content

Clinical efficacy and central mechanism of cerebellar intermittent theta-burst stimulation combined with robot-assisted gait training on balance and walking function of hemiplegic patients with cerebral infarction

Clinical efficacy and central mechanism of cerebellar intermittent theta-burst stimulation combined with robot-assisted gait training on balance and walking function of hemiplegic patients with cerebral infarction

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082918
Enrollment
Unknown
Registered
2024-04-11
Start date
2024-05-05
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Experimental Group ( iTBS + RAGT):Cerebellar iTBS will be conducted using a CCY-I rapid magnetic stimulator coupled with a 70-mm figure-of-8 coil (YIRUIDE Medical, Wuhan, China) by two skilled physiot

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Participants meeting the following criteria will be included: (1) aged between 40 and 70 years; (2) diagnosed with unilateral ischemic or hemorrhagic stroke as confirmed by computed tomography or magnetic resonance imaging; (3) in the subacute stage, 1-6 months post-stroke; (4) having a motor deficit in the lower limbs, with a Fugl-Meyer Assessment scale score for lower extremities (FMA-LE) <34 points and a BBS score < 56 points; (5) able to commit to a 3-week intervention; (6) stable vital signs, no consciousness or cognitive impairment, and able to cooperate during training; (7) voluntary agreement to participate and sign informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria include (1) stroke affecting the cerebellum or brainstem; (2) visual, vestibular, or proprioceptive deficits; (3) pacemakers or intracranial metal implants; (4) history of epilepsy; (5) peripheral neurological lesions impeding action potential measurements; and (6) other conditions interfering with motor function, such as bone fractures, severe osteoporosis, or osteoarthritis.

Design outcomes

Primary

MeasureTime frame
the Berg Balance Scale;

Secondary

MeasureTime frame
Plantar pressure measurements;Trunk Impairment Scale;Timed Up and Go (TUG);2-Minute Walk Test;Resting-state functional magnetic resonance imaging;

Countries

China

Contacts

Public ContactGao Qiang

West China Hospital, Sichuan University

gaoqiang_hxkf@163.com+86 28 8542 2114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026